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Abstract
RNA editing—primarily conversion of adenosine to inosine (A > I)—is a widespread posttranscriptional mechanism,
mediated by Adenosine Deaminases acting on RNA (ADAR) enzymes to alter the RNA sequence of primary transcripts.
Hence, in addition to somatic mutations and alternative RNA splicing, RNA editing can be a further source for recoding
events. Although RNA editing has been detected in many solid cancers and normal tissue, RNA editing in chronic
lymphocytic leukemia (CLL) has not been addressed so far. We determined global RNA editing and recurrent, recoding
RNA editing events from matched RNA-sequencing and whole exome sequencing data in CLL samples from 45 untreated
patients. RNA editing was verified in a validation cohort of 98 CLL patients and revealed substantially altered RNA editing
profiles in CLL compared with normal B cells. We further found that RNA editing patterns were prognostically relevant.
Finally, we showed that ADAR knockout decreased steady state viability of MEC1 cells and made them more susceptible to
treatment with fludarabine and ibrutinib in vitro. We propose that RNA editing contributes to the pathophysiology of CLL
and targeting the RNA editing machinery could be a future strategy to maximize treatment efficacy.
Introduction
Recent data from whole-exome and whole-genome
sequencing approaches revealed a complex genomic land-
scape for many cancer entities [1–3]. In addition to somatic
mutations and alternative splicing, genetic information can
also be altered by RNA editing. Generally, RNA editing is
the posttranscriptional modification of RNA bases, with
adenosine to inosine (A > I) being the most prevailing type
of editing [4, 5]. As I is structurally a guanosine (G) analog,
A to I editing can cause amino acid changes, retargeting of
miRNAs and altered RNA splicing patterns. A to I editing
occurs in almost any tissue from metazoan organisms and
is catalyzed by adenosine deaminases that act on RNA
(ADARs), which, in mammals, comprise ADAR1 (or
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ADAR), ADAR2 (or ADARB1) and catalytically-inactive
ADAR3 family members [6]. ADAR1 has two isoforms, the
full length isoform p150, which is driven from an inflam-
mation dependent promoter and the constitutively expres-
sed, N-terminally truncated isoform p110. Increased RNA
editing was recently detected in many solid cancer entities
compared with healthy tissue, which has been attributed to
an increased expression of ADAR1 in cancer, particularly
the inflammation dependent isoform p150 [7–9]. Global
RNA editing measurements from hundreds of cancer sam-
ples revealed millions of editing sites, most of them
occurring in transcribed noncoding Alu-sites. Alu elements
are short, repetitive DNA stretches with more than one
million copies distributed throughout the genome. Pairs of
inverted copies of Alu elements are preferred targets for
ADARs [10]. Consequently, editing of Alu elements has
been used as an indicator for global editing activity [7, 8].
However, editing in coding regions has also been detected
and some recurrent editing sites affecting coding regions
were reported to influence cancer development and pro-
gression [11–13].
Chronic lymphocytic leukemia (CLL) is a highly het-
erogeneous disease [14] and, accordingly, recent high
throughput sequencing studies identified a large panel of
around 80 putative driver genes from more than 1,000
patients, revealing high interpatient mutational hetero-
geneity [15–17]. However, RNA editing has not yet been
investigated in this cancer entity and it is unknown how the
complex joint effects from genome mutations/aberrations
and RNA editing interrelate with clinical parameters, dis-
ease progression and response to therapies. In this study, we
analyzed RNA editing from matched exomes and tran-
scriptomes of 45 previously untreated CLL patients. From
these data, we established a catalog of recurrent and
recoding editing sites in CLL and validated these sites in a
second CLL cohort and in normal B cell subsets. Our
analysis provides for the first time a detailed insight into
RNA editing in CLL and normal B cells, revealing recurrent
recoding of conserved sites and its association with clinical
parameters in CLL.
Materials and methods
Patients and cell lines
Peripheral blood from chemo-naïve CLL patients participat-
ing in a previously reported clinical trial (AGMT-REVLIRIT
trial, ClinicalTrials.gov Identifier: NCT00738829 and
NCT01703364) [18] with first line treatment with lenalido-
mide in combination with fludarabine and rituximab
was collected upon informed consent and ethical approval
by the Ethics Committee of the Province of Salzburg
(415-E/1287/4–2011, 415-E/1287/8–2011). Sampling was
performed prior treatment start and CLL cells were obtained
by density gradient centrifugation and B-CLL Cell Isolation
kit (Miltenyi Biotec). Cell purity was >90% in all samples.
The determination of prognostic markers was performed
routinely at our department as described previously [19].
DNA and RNA was purified using DNeasy Blood and Tissue
kit or RNeasy Mini kit (both Qiagen), respectively. Patient
details and type of analysis are given in supporting Table 1.
Primers are listed in supporting Table S2. RNA/DNA
sequencing data from AGMT-REVLIRIT patients and
MEC1 cells are available under BioProject PRJNA540189 at
https://www.ncbi.nlm.nih.gov/sra. In addition, RNA sequen-
cing and clinical data from CLL samples and normal B cells
were downloaded from the European Genome-phenome
Archive (EGAS00001000374) [20].
Results
Characteristics of patients
We studied RNA editing in 45 previously untreated CLL
patients prior to first line therapy with fludarabine/rituximab
combined with escalating doses of lenalidomide (AGMT-
REVLIRIT study [18], see Material and Methods). The
mean age of patients was 66 years (range 43–80). 20 of 45
patients (44%) were female and 25 were male (56%). 19
patients had a mutated IGHV (42%), 21 were IGHV
unmutated (47%) and five patients (11%) had undefined
IGHV status. 13 patients (29%) had ‘high risk’ FISH
cytogenetics with 17p and/or 11q deletions (Table 1 and
supporting Table S1). We were able to isolate matched
RNA and genomic DNA from all 45 patients.
Editing of Alu sites correlates with ADAR expression
First, we calculated RNA editing within Alu regions
(repetitive, mostly noncoding elements in the genome) in
CLL samples from RNA sequencing data as previously
described [7]. As 99% of global RNA editing is confined to
Alu regions, RNA editing in Alu sites reflects the overall A
> I RNA editing activity of a particular sample. We mea-
sured all edited adenosine within Alu elements (unique Alu
editing sites) as well as the averaged editing level across all
Alu adenosines, weighted by their relative expression (Alu
editing index; AEI) [7]. We detected unique editing sites
ranging from 177,720 up to 537,995 events per sample and
an AEI ranging from 1.22 to 2.45 arbitrary units in our CLL
cohort. In line with previous results from other cancer
entities, we found that editing directly correlated with
ADAR mRNA expression in the IGHV mutated samples,
irrespective of the ADAR isoform (p110 or p150)
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expressed. However, correlation of AEI with p110 was
more significant compared with p150 (Fig. 1a). Surpris-
ingly, unique Alu editing sites and AEI did not correlate
with ADAR p110 or p150 expression in the IGHV unmu-
tated samples (Fig. 1a).
As we observed RNA editing activity to correlate with
ADAR levels only in IGHV mutated CLL, we asked whe-
ther a set of recently identified editing cofactors [21] would
be differentially expressed in IGHV mutated versus
unmutated CLL. Indeed, we observed that three editing
factors (CCDC9, TIMM17A, and MRPL47) were sig-
nificantly differentially expressed according to IGHV
mutation status (false discovery rate adjusted p < 0.05;
supporting Table S3).
RNA editing in coding regions
RNA editing in Alu repeats is a proxy for global RNA
editing activity, but gives little information on recoding
events, as those are mostly located outside Alu elements.
In order to determine RNA editing in coding regions, we
next screened for RNA-DNA single nucleotide differ-
ences (RDDs) from matched RNA-sequencing/whole-
exome sequencing (WES) data from our 45 patients.
Screening for differences in matched RNA/DNA pairs
revealed a total of 80,150 RDDs in 45 samples. Similar to
a previous report [22], our RDD analysis yielded all
possible base changes in recoding and nonrecoding events
(Fig. S1); however, RDDs present in Alu regions (6864
events) as determined by the UCSC repeat masker track,
were mostly of the A > I type, consistent with the finding
that A > I editing occurs predominantly in Alu regions
(Fig. S1). Among all RDDs, we found between 196 and
686 A > I editing events per sample. The number of A > I
editing sites correlated particularly with ADAR p110
expression irrespective of the IGHV mutation status
(Fig. 1b) and with the number of unique editing sites in
Alu regions particularly in IGHV mutated samples
(Fig. 1c). Notably, ADAR levels, particularly isoform
p110, were generally higher in IGHV unmutated CLL
samples (Fig. 1d). From the total of 18,854 A > I RDDs
from all 45 CLL, 3773 (20%) mapped to exonic regions of
which 2773 (73.5%) resulted in amino acid changes
(Fig. 1e). From the 2773 nonsynonymous editing events,
we found a set of 19 editing sites confined to 14 genes
that were recurrently edited in at least 5 out of 45 patients,
with no apparent IGHV specific differences (Fig. 2a,
supporting Table S4). These genes are associated with 55
diverse biological pathways (Fig. 2b).The recurrent edit-
ing sites were individually checked for ambiguity or
misalignment using BLAST search and for artefacts using
Integrative Genome Viewer (IGV, Fig. 2c). Except for
editing of ZNF417 (chr19:58420940), we found all of
these sites already described as A > I editing targets in
published datasets [23–25], and they matched the con-
sensus ADAR deamination motif with preference for
underrepresentation of G bases at the −1 position and
overrepresentation of G at the +1 position [26] (Fig. 2d).
Of note, we did not observe apparent correlations of
editing frequency with expression levels of the respective
genes, except for FLNB, NEIL1, and PI4K2A editing,
which showed a weak positive correlation with expression
(Fig. S2).
Table 1 Patient characteristics of CLL cohorts.
Parameters AGMT-REVLIRIT
cohort [18]
CLL validation
cohort [20]
Total number (%) 45 (100) 98 (100)
Sex
Male (%) 25 (56) 68 (69)
Female (%) 20 (44) 30 (31)
Age (years)
Mean 65.8 66.7
Range 43–80 38–89
Duration of disease (years)
Mean 3.8 5.4
Range 0–10.3 0–21.9
RAI stage at diagnosis
nda 2 (4)
I 7 (16)
II 16 (36)
III 12 (27)
IV 8 (18)
Binet stage at diagnosis
nda 2 (2)
A 91 (93)
B 4 (4)
C 1 (1)
Molecular risk parameters
Unmutated Ig VH 21 (47) 43 (44)
IGHV nda 5 (11) 2 (2)
FISH karyotype
del11q 9 (20) 14 (14.3)
del13q 29 (64) 51 (52.0)
del17p 4 (9) 4 (4)
trisomy 12 6 (13) 14 (14)
normal karyotype 5 (11) 23 (23)
karyotype nda 1 (2) 2 (2)
Treatment status
Untreated at sampling 45 (100) 98 (100)
Untreated at last
follow up
0 (0) 39 (40)
IGHV immunoglobulin variable heavy chain, FISH fluorescence in situ
hybridization, nda no data available.
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Recurrent RNA editing patterns are different
between CLL and normal B cells
Next, we accessed RNA-seq data from a validation cohort
of 98 CLL samples from Ferreira et al. (Table 1) [20], which
included normal naïve B cells as well as class switched and
nonclass switched memory B cells (n= 9 for each normal B
cell subset), allowing comparison of CLL RNA editing with
that from different normal B cell subsets. From these RNA-
seq data, we extracted A/G variant frequencies at the 19
editing sites. While in most samples from the CLL cohort
from Ferreira et al the coverage of the CDK13 gene was too
low for assessing RNA editing - and we hence excluded the
four CDK13 sites from all further analyses—we found that
the remaining 15 out of these 19 sites were also robustly
edited in the validation cohort. Moreover, depending on the
IGHV mutation status, editing depths (i.e., editing fre-
quencies) from most of these sites were significantly dif-
ferent compared with normal B cell subsets, indicating
aberrant RNA editing in CLL. While normal B cell subsets
had distinctive RNA editing depths for each site, RNA
editing in CLL cells was highly variable (Fig. S3A). The
global RNA editing activity as measured by the AEI was
significantly increased in naïve B cells compared with CLL
cells and to other normal B cell subsets (Fig. S3B). In
addition, the AEI was significantly lower in IGHV unmu-
tated CLL cases compared with IGHV mutated samples
(Fig. S3C) and the variance from CLL cells was
exonic 20.01%
intergenic 1.62%
intronic 53.56%
ncRNA_exonic 7.89%
ncRNA_intronic 4.95%
other 0.15%
splicing 5.3%
UTR3 5.78%
UTR5 0.74%
A>I RDDs (total: 18,854)
nonsynonymous 73.5%
stoploss 0.08%
synonymous 25.55%
unknown 0.87%
exonic A>I RDDs (total: 3,773)
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Fig. 1 A > I editing in CLL. a Unique Alu editing sites and Alu
editing index (AEI) were determined in CLL samples and correlated
with normalized expression of ADAR1 (ADAR) isoforms p110
(upper panel) and p150 (lower panel) according to IGHV mutation
status. b A to I (RNA-DNA single nucleotide differences) RDDs were
correlated with ADAR isoforms p110 and p150. c A > I RDDs were
correlated with unique Alu editing sites according to IGHV mutation
status. d ADAR mRNA levels as well as ADAR isoforms p110 and
p150 levels were determined for IGHV mutated and unmutated CLL
samples. Significances calculated using unpaired t test. e Functional
consequences of A > I RDDs are depicted as pie charts for total A > I
editing events and for exonic A > I RDDs.
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significantly greater than that from normal cells (F= 4.84,
p= 0.00003), underpinning increased variability in RNA
editing activity in malignant cells. Conversely, expression
of ADAR isoform p150 is significantly higher in CLL
compared with normal B cells and corroboratively to the
AGMT-REVLIRIT cohort, ADAR expression is slightly
Fig. 2 Recurrent recoding A >
I editing in CLL. a Heat map of
editing frequencies of 19
recurrent A > I editing sites
within 14 genes in CLL cells
from the AGMT-REVLIRIT
cohort [18]. Patient IDs are
depicted below the heat map.
b Mapping of 14 edited genes
to biological pathways.
c Integrative Integrative
Genomics Viewer screenshot
(http://software.broadinstitute.
org/software/igv/) of RNA-seq
and WES data of exemplary
edited genes. d Sequence
context of A > I editing sites
from editing sites shown in (a).
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increased in IGHV unmutated samples (Fig. S3D). Fur-
thermore, in line with the AGMT-REVLIRIT cohort
(Fig. S2), we again observed no apparent correlation of
editing depths with expression levels, neither for CLL cells
(Fig. S4) nor for normal B cells (Fig. S5).
Clinical relevance of A > I RNA editing
Next, we performed hierarchical clustering of editing sites
from the Ferreira cohort [20]. This resulted in a robust
separation of normal naive B cells, memory B cell subsets
and four groups of CLL samples, which differed in number
and editing depths of the recurrent editing events (Fig. 3a).
This again confirmed specific RNA editing patterns for each
normal B cell subset and aberrant RNA editing in CLL. The
four groups defined by clustering of RNA editing patterns
were largely independent from IGHV mutation status, Binet
staging and chromosomal aberrations, except for cluster
1 showing association with increased presence of del11q
(Fig. 3b). In this cluster 1, the AEI was significantly
decreased compared with other RNA editing clusters and
compared with normal naive B cell subsets (Fig. S6A).
However, ADAR isoform expression was only slightly
different between the individual clusters (Fig. S6B).
Moreover, patients within cluster 1 had significantly shor-
tened time to first treatment (TTFT) compared with
other patients. For time from diagnosis, the median
TTFT for cluster 1 was 53.6 versus 117.3 months for
noncluster 1 patients, HR= 2, 95%CI= 1.1–3.5, p= 0.017
(log-rank test; Fig. 3c). However, in multivariate analysis,
IGHV mutation status remained the most powerful inde-
pendent prognostic parameter in this cohort (supporting
Table S5).
To validate the results from the Ferreira cohort, we
performed hierarchical clustering of editing sites from the
AGMT-REVLIRIT cohort (n= 45) [18], which yielded 7
distinct RNA editing clusters (Fig. S7A). In this analysis,
cluster 5 is highly similar to cluster 1 from the Ferreira
cohort, characterized by high NEIL1 editing, intermediate
RNA editing of COG3 and low editing of any other site.
Again, this cluster showed the shortest time to first treat-
ment of 31.9 months compared with 42 months for all
noncluster 5 patients, although this was not statistically
significant (HR= 2.03; 95%CI= 0.88–4.7; p= 0.09; log
rank test, Fig. S7B). However, in multivariate analysis,
neither IGHV mutation status, nor cytogenetics remained a
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significant independent prognostic parameter, probably due
to small sample size of this cohort (supporting Table S6).
Strikingly, stratifying patients from the Ferreira cohort
according to IGHV mutation status revealed that editing-
cluster 1 patients had significantly shortened time to first
treatment particularly within the IGHV mutated cases
(Fig. 4a). As RNA editing is potentially a dynamic process,
which may evolve with disease progression, we next cal-
culated treatment-free intervals for patients considering time
from diagnosis versus time from sampling. Thereby we
found that the shortened treatment-free interval for IGHV
mutated patients within editing cluster 1 was even more
significant for time from sampling compared with time from
diagnosis. For time from sampling, the median TTFT for
cluster 1 IGHV mutated patients was 7.68 versus not
reached for noncluster 1 IGHV mutated patients, HR=
4.92, 95%CI= 2–12, p= 0.0005 (log-rank test; Fig. 4a left
graph). For time from diagnosis, the median TTFT for
cluster 1 IGHV mutated patients was 53.6 versus not
reached for noncluster 1 IGHV mutated patients, HR=
4.28, 95%CI= 1.8–10, p= 0.0012 (log-rank test; Fig. 4a
right graph). For IGHV unmutated patients, RNA editing
clusters did not show any prognostic relevance (Fig. 4b). In
multivariate analyses, the RNA-editing cluster remained the
most significant independent prognostic factor amongst
chromosomal aberrations del11q, del17p, del13q, and tris-
omy12 for IGHV mutated patients (Fig. 4c).
In the AGMT-REVLIRIT cohort, only two patients from
RNA editing cluster five were IGHV mutated, rendering the
log-rank test not significant (Fig. S8). As for patients from
the AGMT-REVLIRIT cohort sampling was done at treat-
ment start, the treatment-free interval from sampling date
was not calculable. Notably, we also analyzed time to
progression upon treatment of patients in the two CLL
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cohorts. While the RNA editing cluster did not significantly
predict progression free survival (PFS) in the Ferreira
cohort, PFS was prolonged in patients with RNA editing
cluster 5 from the AGMT-REVLIRIT cohort (Fig. S9).
To identify possible reasons for the differential editing
activity in normal versus malignant cells, we again analyzed
putative cofactors involved in editing [21]. We found many
editing factors differentially expressed between normal B
and CLL cells at high significance. In addition, six factors
were differentially expressed in CLL according to IGHV
mutation status. However, we only found a few factors
differentially expressed between individual editing clusters
(supporting Table S7). In addition, some RNA binding
proteins, which were recently shown to affect RNA editing
[27] were found to be differentially expressed within the
respective CLL clusters and according to IGHV status of
CLL (supporting Table S8).
ADAR deficiency sensitizes toward CLL treatment
in vitro
As our data showed that RNA editing patterns correlate
with prognosis in CLL, we tested whether RNA editing
activity directly affects viability of CLL cells and drug
sensitivity. Therefore, we knocked out ADAR in the pro-
lymphocytic CLL cell line MEC1 [28] (Fig. 5a). We ver-
ified the knockout by Sanger sequencing (Fig. 5a) and
additionally monitored RNA editing of selected editing sites
in MEC1 versus MEC1 ADAR-knockout cells by Sanger-
sequencing. From six genes analysed (CDK13, CCNI,
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Fig. 5 ADAR knockout in MEC1 cells sensitizes toward in vitro
treatment. a Schematic representation of ADAR exon 2 and DNA/
protein sequence of the CRISPR/Cas9 target site (protospacer adjacent
motif is underlined) for the two ADAR isoforms p110 and p150.
Sanger sequence of the target site from MEC1 ADAR-knockout cells
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editing sites in MEC1 and MEC1 ADAR knockout cells. d Unique Alu
editing sites and Alu editing index (AEI) for MEC1 and MEC1 ADAR
knockout cells. e Representative viability stains (measured by flow
cytometry and 7AAD/AnnexinV) and dot plot from n= 4 independent
experiments (left graph) and longitudinal cell counts (right graph,
n= 3) from MEC1 and MEC1 ADAR knockout cells. f Representative
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treated with different doses of indicated drugs in vitro for 72 h fol-
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cells) were set to 100%. Significances calculated using unpaired t test
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plots show mean values); *p= 0.01; **p < 0.01.
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FLNB, COG3, COPA, BLCAP), we detected robust editing
of two sites in MEC1 cells (FLNB, chr3:58141791;
BLCAP, chr20:36147572), which remained unedited in
ADAR-knockout cells, verifying that these editing events
were indeed ADAR dependent (Fig. 5b). To more thor-
oughly investigate ADAR dependent RNA editing in
MEC1, we performed RNA-seq of MEC1 and MEC1
ADAR-knockout cells. Thereby, we found that from our set
of 19 recurrent editing sites, AZIN1, PI4K2A and TOR1B
sites were also edited in MEC1 cells but not in the knockout
cells (Fig. 5c). Furthermore, the AEI and unique Alu editing
sites were dramatically decreased in absence of ADAR
(Fig. 5d). In addition, we screened MEC1 cells for editing at
sites recently described in a glioblastoma cell line and pri-
mary breast cancer samples [29], which revealed that many
of these sites were also edited in MEC1 cells in an ADAR
dependent manner (supporting Table 9).
We further noticed that knockout of ADAR in
MEC1 cells already resulted in a slight and significant
decrease of viability, proliferation, and cells in S/M/G2
phase of the cell cycle (Fig. 5e, f). Furthermore, our RNA-
seq data revealed many differentially expressed genes
between wildtype and knockout cells (Fig. 5g, supporting
Table 10) resulting in significantly over- and under-
represented gene sets and pathways in gene ontology and
KEGG (Kyoto Encyclopedia of Genes and Genomes)
pathway analysis. However, we did not find significant
differences in cell cycle, apoptosis, or IFN signaling path-
ways (supporting Tables S11 and S12). Notably, RNA-seq
revealed that both ADAR isoforms p110 and p150 were
expressed at similar levels in MEC1 cells (Fig. S10A),
which roughly resembles p110/p150 ratios found in primary
CLL samples (Figs. 1d and S10B). Finally, we tested
whether ADAR knockout cells showed different sensitivity
toward current treatments in vitro. Therefore, we incubated
wildtype and knockout MEC1 cells with different doses of
fludarabine, and with the BTK inhibitor ibrutinib and the
BCL2 inhibitor venetoclax and monitored viability of cells.
We found that knockout cells showed increased sensitivity
toward treatment particularly with fludarabine and ibrutinib
(Fig. 5h). While MEC1 cells were resistant to 25 µM flu-
darabine and 10 µM ibrutinib, the ADAR knockout cells
showed significantly decreased viability at these
concentrations.
Discussion
A to I RNA editing was recently shown to substantially
contribute to transcript diversification in health and disease
and an increased global editing activity (determined by Alu-
editing) was shown to frequently associate with poor clin-
ical outcome in solid cancer [7]. In contrast to somatic
mutations and genome aberrations, RNA editing enables
alterations of genome information in a very dynamic and
flexible way, as editing depths may vary between daughter
cells and in dependence of interaction with microenviron-
mental niches. In this study, we describe for the first time
RNA editing in CLL and defined 19 recurrent, nonsynon-
ymous editing sites within 14 genes. Although editing sites
were shared between normal and malignant cells, the edit-
ing pattern was highly characteristic for CLL or normal
subsets, revealing that while editing is homogenous in
normal B cell subsets, it became very heterogeneous with
high variance in malignant cells. As RNA editing is not
simply determined by ADAR activity but also by many
RNA binding proteins, we assume that subtle changes in
their expression patterns likely contribute to the observed
aberrant RNA editing activity in CLL [27]. This assumption
is supported by our finding that many described editing
cofactors [21, 27] were differentially expressed between
CLL subgroups and also compared with normal B cells. In
addition, ADAR isoform expression is different between
CLL and B cells, with CLL samples showing higher ADAR
p150 levels than B cells. This could be likely due to a more
inflammatory microenvironment in CLL patients, which
could also contribute to the aberrant RNA editing patterns
observed in CLL. Surprisingly, ADAR p110/p150 ratios
were slightly different between the two CLL cohorts, which
could be due to differences in RNA preparation, handling,
library preparation or sequencing.
RNA editing patterns were highly specific for normal
naïve and memory B cells, corroborating recent results that
ADAR mediated RNA editing is required for normal B cell
development [30]. For CLL cells, we defined a specific
RNA editing cluster, which was associated with shortened
time to first treatment in two CLL cohorts, particularly in
IGHV mutated cases. Strikingly, the global editing activity
as determined by the AEI was lower in patients with
shortened TTFT and lower compared with normal naive B
cells. This is in contrast to many solid cancers, where RNA
editing rates were higher in malignant versus healthy tissue
[7]. Increased RNA editing in cancer is thought to dampen
anti-cancer immunity, as editing of Alu-elements prevents
their binding to dsRNA sensors, which leads to a robust
interferon response [5, 31]. In line with this, antitumor
immunity was fundamentally increased in mouse models
using ADAR-deficient tumor transplants [32, 33]. In this
regard, the overall low RNA editing activity in CLL could
reflect a general low anti-cancer immunity and low immu-
nologic pressure in CLL, which would be in line with the
observation that CLL patients generally do not respond to
immune reactivation using immune checkpoint inhibitors
[34]. Hence, it would be interesting to test whether ADAR
inhibition in CLL would somehow improve anti-CLL
immune responses in patients.
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So far, many cancer cell lines have shown increased
vulnerability toward type-I interferon signaling upon abla-
tion of ADAR [35]. Results from the present study showed
that ADAR loss also increases sensitivity toward fludar-
abine and ibrutinib in vitro, revealing that therapeutic
inhibition of ADAR not only improves antitumor immunity
but likely also potentiates drug efficacy. The observed
synergism between ADAR ablation and drug treatment may
either be based on potentiation of the IFN-response, which
is elicited upon ADAR loss as well as upon many treat-
ments [36], or alternatively, recoding of edited genes may
affect distinct biological pathways, synergizing with parti-
cular drug effects. Surprisingly, although we found many
differentially expressed genes and gene sets upon ADAR
loss in MEC1 cells, our data did not show particular
changes in IFN genes and IFN pathways. This might indi-
cate that gene expression differences and decreased viability
upon ADAR loss would rather result from non-
synonymously edited transcripts than from an increased
IFN-response upon absence of Alu editing in MEC1 cells.
Summarizing, we showed that RNA editing substantially
contributes to protein recoding in CLL. Our data on
MEC1 cells further suggest that interference with ADAR
function renders CLL cells more susceptible to distinct ther-
apeutic regimens in vitro, which makes ADAR an interesting
target for future combination-treatment strategies.
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